What research projects has the EORTC performed with industry?

RECIST, Response Evaluation Criteria in Solid Tumors, was developed for use in clinical trials with a primary endpoint of objective response.

Criteria for DLT/MTD recommended dose for phase I for non cytotoxic agents

Meta-analysis intended to qualify durable complete response as a surrogate endpoint for progression-free survival in follicular lymphoma. EORTC trial 20921

Discussions underway for a project to validate relapse-free survival as a surrogate to overall in adjuvant melanoma.

EORTC is a major participant to the Innovative Medicine Initiative (IMI) being involved in programs such as PharmaTrain, being the managing entity of QuIC-ConCePT, an imaging program aiming at the qualification and validation of biomarkers, and Eupati, a patient initiative.

Find us

Avenue Emmanuel Mounier, 83/11
Brussels 1200
Belgium

Contact us

Follow us

Funding